Navigation Links
Venture Capital Veteran John Brooks Joins Life Science Investment Bank Johnston Blakely & Company
Date:5/4/2009

BOSTON, May 4 /PRNewswire/ -- Johnston Blakely & Company, LLC, a Boston-based life science investment bank, is pleased to announce that John L. Brooks, III has joined the firm as senior advisor. In this role, Mr. Brooks will participate with the firm on internal and client-related activities including private equity placements and merger & acquisition advisory services, with a particular focus on medical device transactions. "We are thrilled to welcome John Brooks to the Johnston Blakely family," remarked Johnston Blakely founder Benjamin Conway. "Not only does John bring to the firm and its clients a track record of success in both venture capital and the medical device industry, but his decision to join us is also a strong endorsement of Johnston Blakely and its capabilities."

John Brooks co-founded the venture capital firm Prism Venture Partners. During his ten-year tenure with Prism, the firm raised $1.25 billion across six venture funds. While with Prism, Mr. Brooks led the firm's healthcare investment activities including its role in the creation of companies such as Insulet Corporation. His previous experience also includes senior management positions at Pfizer, both with Pfizer/Valleylab as General Manager and with Pfizer/Strato. Mr. Brooks has held several vice president of finance and operations positions at successful venture-backed companies and spent over 10 years in public accounting and consulting focused on supporting venture backed entrepreneurs.

In addition to his current involvement on the boards of certain Prism portfolio companies, John Brooks is vice chairman of the Board of Trustees of the Joslin Diabetes Center where he is also chairman of the finance committee, a member of the steering committee of Mass Medic's MedTech Ignite (Inspiring Growth in New Innovative Technology Enterprises) program and is on the Draper BioAdvisory Board.

About Johnston Blakely & Company

Johnston Blakely & Company, LLC is a Boston-based investment bank offering private equity placement and merger & acquisition-related financial advisory services to companies in the life science sector. The firm incorporates the venture capital tradition of comprehensive company involvement into investment banking engagements to deliver superior results for its clients. More than investment banking...inVenture banking(TM).

Johnston Blakely is a registered broker/dealer and member of FINRA/SIPC.


'/>"/>
SOURCE Johnston Blakely & Company, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. UMass Boston Opens Venture Development Center to Expand R&D Activity
2. Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities
3. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
4. CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture
5. NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business
6. Cynvec to Present at the BIO National Venture Conference
7. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
8. Merck Serono Launches Strategic Venture Capital Fund
9. StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies
10. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
11. Alltech, Mitsui and Asahi Breweries Create New Venture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Columbia and MENLO PARK, Calif. ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused ... announced that it will present at the 18 th ... February 8, 2016 at 10:00 a.m. EST in ... , DelMar,s president and CEO, will provide an update on ...
(Date:2/4/2016)... ... 2016 , ... Franz Inc. , an early innovator ... been recognized As “ Best in Semantic Web Technology - USA & Leader ... it’s our priority to showcase prominent professionals who are excelling in their industry ...
(Date:2/3/2016)... 3, 2016  With the growing need for ... is underway, therapies such as monoclonal antibodies, recombinant ... host of indications are in high demand. Conventionally ... development and production of these therapeutics. However, due ... high costs, novel approaches and novel expression systems ...
(Date:2/3/2016)... ... February 03, 2016 , ... ProMIS Neurosciences is currently in ... to misfolded, propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company ... , Following on from the first misfolded Amyloid beta target announced on Nov. ...
Breaking Biology Technology:
(Date:1/21/2016)... India , January 21, 2016 ... According to a new market research report "Emotion Detection ... and Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020", published by ... is expected to reach USD 22.65 Billion by ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., a ... simplifies the use and access of ubiquitous on-premise ... partnership with American Cyber.  ... experience leading transformational C4ISR and Cyber initiatives in ... the latest proven technology solutions," said Steve ...
(Date:1/11/2016)... Jan. 11, 2016 Synaptics Incorporated (NASDAQ: ... today announced that its ClearPad ® TouchView ™ ... won two separate categories in the 8 th ... Best Technology Breakthrough. The Synaptics ® TDDI solution ... supply chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):